51. Novel RP-HPLC based assay for selective and sensitive endotoxin quantification
- Author
-
Martin Pattky, Anika Hoffmann, Florian J. Heiligtag, Brian Frank, Mathieu Zollinger, Mònica Bassas-Galia, Fabio Stephan, Ralph Daumke, Manfred Zinn, Blanka Bucsella, and Franka Kalman
- Subjects
0303 health sciences ,Chromatography ,Bacteria ,030306 microbiology ,Chemistry ,General Chemical Engineering ,General Engineering ,Rare sugar ,Fluorescence spectroscopy ,Analytical Chemistry ,Endotoxins ,03 medical and health sciences ,Hydrolysis ,Depth filter ,Gram-Negative Bacteria ,Animals ,Biological Assay ,Fluorescent derivative ,Chromatography, High Pressure Liquid ,030304 developmental biology - Abstract
The paper presents a novel instrumental analytical endotoxin quantification assay. It uses common analytical laboratory equipment (HPLC-FLD) and allows quantifying endotoxins (ETs) in different matrices from about 109 EU per mL down to about 40 EU per mL (RSE based). Test results are obtained in concentration units (e.g. ng ET per mL), which can then be converted to commonly used endotoxin units (EU per mL) in case of known pyrogenic activity. During endotoxin hydrolysis, the endotoxin specific rare sugar acid KDO is obtained quantitatively. After that, KDO is stoichiometrically reacted with DMB, which results in a highly fluorescent derivative. The mixture is separated using RP-HPLC followed by KDO-DMB quantification with a fluorescence detector. Based on the KDO content, the endotoxin content in the sample is calculated. The developed assay is economic and has a small error. Its applicability was demonstrated in applied research. ETs were quantified in purified bacterial biopolymers, which were produced by Gram-negative bacteria. Results were compared to LAL results obtained for the same samples. A high correlation was found between the results of both methods. Further, the new assay was utilized with high success during the development of novel endotoxin specific depth filters, which allow efficient, economic and sustainable ET removal during DSP. Those examples demonstrate that the new assay has the potential to complement the animal-based biological LAL pyrogenic quantification tests, which are accepted today by the major health authorities worldwide for the release of commercial pharmaceutical products.
- Published
- 2020